News | February 23, 2023
Research underscores Beyfortus’ potential to prevent RSV disease in infants
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Subscribe To Our Newsletter & Stay Updated
